Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing

[1]  A. Clayton,et al.  Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer , 2022, Biomolecules.

[2]  S. Herrell,et al.  Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease , 2022, Nature Communications.

[3]  R. Zhou,et al.  BCAM Deficiency May Contribute to Preeclampsia by Suppressing the PIK3R6/p-STAT3 Signaling , 2022, Hypertension.

[4]  Yongjie Zhang,et al.  Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data , 2022, Frontiers in Immunology.

[5]  Huasong Huo,et al.  Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies , 2022, Prostate Cancer and Prostatic Diseases.

[6]  J. Qiu,et al.  Construction and Verification of a Fibroblast-Related Prognostic Signature Model for Colon Cancer , 2022, Frontiers in Genetics.

[7]  H. Klocker,et al.  Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer , 2022, Molecular Cancer.

[8]  N. Erez,et al.  Cancer-associated fibroblasts in the single-cell era , 2022, Nature Cancer.

[9]  J Zhang,et al.  Bioinformatic analysis of cancer-associated fibroblast related gene signature as a predictive model in clinical outcomes and immune characteristics of gastric cancer , 2022, Annals of translational medicine.

[10]  J. Schlom,et al.  Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication , 2022, The Journal of clinical investigation.

[11]  Xiang Zhang,et al.  circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis , 2022, Molecular cancer.

[12]  C. Xue,et al.  More Than Just Cleaning: Ubiquitin-Mediated Proteolysis in Fungal Pathogenesis , 2021, Frontiers in Cellular and Infection Microbiology.

[13]  Chen Liang,et al.  Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.

[14]  Hua Li,et al.  Bisphenol S promotes the progression of prostate cancer by regulating the expression of COL1A1 and COL1A2. , 2021, Toxicology.

[15]  R. Kalluri,et al.  Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.

[16]  Jing Yu,et al.  Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling , 2021, Frontiers in Cell and Developmental Biology.

[17]  Robert F. Gruener,et al.  oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..

[18]  Min Lu,et al.  Downregulation of tumor‐derived exosomal miR-34c induces cancer‐associated fibroblast activation to promote cholangiocarcinoma progress , 2021, Cancer cell international.

[19]  Samantha M. Carlisle,et al.  Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1. , 2021, Immunity.

[20]  S. Nakajima,et al.  Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma , 2021, Oncology letters.

[21]  E. Puré,et al.  Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy , 2020, eLife.

[22]  Jing Wang,et al.  Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion , 2020, Nature Communications.

[23]  Yifeng Jing,et al.  Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis , 2020, Journal of Experimental & Clinical Cancer Research.

[24]  T. Rebbeck,et al.  Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients , 2020, Clinical Cancer Research.

[25]  A. Ganesan,et al.  Targeting B7‐1 in immunotherapy , 2020, Medicinal research reviews.

[26]  Hao Li,et al.  Broadly conserved roles of TMEM131 family proteins in intracellular collagen assembly and secretory cargo trafficking , 2020, Science Advances.

[27]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[28]  M. Yao,et al.  Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis , 2019, World Journal of Urology.

[29]  P. Albers,et al.  Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[31]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[32]  K. Iguchi,et al.  Interleukin‐6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation , 2018, The Prostate.

[33]  S. Barry,et al.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.

[34]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[35]  M. Dunning,et al.  Identification of potential therapeutic targets in prostate cancer through a cross‐species approach , 2018, EMBO molecular medicine.

[36]  R. Mehra,et al.  Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. , 2017, European urology.

[37]  I. Mills,et al.  Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Yongrui Piao,et al.  Analysis of Tim-3 as a therapeutic target in prostate cancer. , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[39]  M. Rubin,et al.  Inherited determinants of early recurrent somatic mutations in prostate cancer , 2017, Nature Communications.

[40]  D. Neal,et al.  Asporin is a stromally expressed marker associated with prostate cancer progression , 2017, British Journal of Cancer.

[41]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[42]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[43]  Lisa U. Magnusson,et al.  Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment , 2016, The Prostate.

[44]  S. Turley,et al.  Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.

[45]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[46]  Jennifer R. Rider,et al.  Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer , 2015, Clinical Cancer Research.

[47]  Pierre Drion,et al.  Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer , 2015, PLoS medicine.

[48]  S. Vowler,et al.  Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study , 2015, EBioMedicine.

[49]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[50]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[51]  A. Anderson Tim-3, a negative regulator of anti-tumor immunity. , 2012, Current opinion in immunology.

[52]  Renaud Gaujoux,et al.  A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.

[53]  R. Tibshirani The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[54]  D. Gfeller,et al.  EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. , 2020, Methods in molecular biology.